Clinical predictors of rectal cancer response after neo-adjuvant (Chemo)Radiotherapy in Australia and New Zealand: Analysis of the Bi-National Colorectal Cancer Audit (BCCA)

Eur J Surg Oncol. 2023 Nov;49(11):107070. doi: 10.1016/j.ejso.2023.107070. Epub 2023 Sep 9.

Abstract

Pathological complete response (pCR) is observed in 11-26% of locally advanced rectal cancers undergoing neoadjuvant chemoradiotherapy (nCRT). This study aims to determine pCR rates and clinicopathological predictors in the Australian and New Zealand (ANZ) cohort. The Bi-National Colorectal Cancer Audit (BCCA) was interrogated for all rectal cancer patients who underwent nCRT prior to surgical resection between 2007 and 2020. Patients were divided in two groups: pCR (AJCC tumour regression grade 0) and partial/no response (pPR, regression grade 1,2 or 3). In total, 3230 patients were included. Rates of pCR and pPR were 704 (21.8%) and 2526 (78.2%), respectively. Long-course nCRT (p < 0.0001), lower clinical tumour stage (cT; p < 0.0001), and nodal stage (cN; p = 0.003) were associated with pCR on univariate analysis. On multivariable analysis, cN0 stage and long-course nCRT remained independent factors for a pCR. Awareness of these predictors provides valuable information when counseling patients regarding prognosis and treatment options.

Keywords: Chemoradiotherapy; Neoadjuvant therapy; Rectal cancer; Response; Tumour regression grade.

MeSH terms

  • Australia / epidemiology
  • Chemoradiotherapy
  • Humans
  • Neoadjuvant Therapy*
  • Neoplasm Staging
  • New Zealand / epidemiology
  • Rectal Neoplasms* / pathology
  • Rectal Neoplasms* / therapy
  • Retrospective Studies
  • Treatment Outcome